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INTRODUCTION: As patient assessment of health-related quality of life (HRQOL) in
cancer clinical trials has increased over the years, so has the need to attach
meaningful interpretations to differences in HRQOL scores between groups and
changes within groups. Determining what represents a minimally important
difference (MID) in HRQOL scores is useful to clinicians, patients and researchers,
and can be used as a benchmark for assessing the success of a healthcare
intervention. Our objective is to provide an evidence-based protocol to determine
MIDs for the European Organisation for Research and Treatment for Cancer
Quality of life Questionnaire core 30 (EORTC QLQ-C30). We will mainly focus on
MID estimation for group-level comparisons. Responder thresholds for individual-
level change will also be estimated.
METHODS AND ANALYSIS: Data will be derived from published phase II and III
EORTC trials that used the QLQ-C30 instrument, covering several cancer sites. We
will use individual patient data to estimate MIDs for different cancer sites
separately. Focus is on anchor-based methods. Anchors will be selected per disease
site from available data. A disease-oriented and methodological panel will provide
independent guidance on anchor selection. We aim to construct multiple clinical
anchors per QLQ-C30 scale and also to compare with several anchor-based
methods. The effects of covariates, for example, gender, age, disease stage and so
on, will also be investigated. We will examine how our estimated MIDs compare
with previously published guidelines, hence further contributing to robust MID
guidelines for the EORTC QLQ-C30.
ETHICS AND DISSEMINATION: All patient data originate from completed clinical
trials with mandatory written informed consent, approved by local ethical
committees. Our findings will be presented at scientific conferences, disseminated
via peer-reviewed publications and also compiled in a MID 'blue book' which will be
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